Similar Search Results

Health Economic and Infectious Disease Modelling: A Guide to Merging Streams

Anonychuk, Andrea; Krahn, Murray - In: PharmacoEconomics 29 (2011) 5, pp. 367-369

Persistent link: https://www.econbiz.de/10010614410

New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses

Mapel, Douglas W.; Roberts, Melissa H. - In: PharmacoEconomics 30 (2012) 10, pp. 869-885

such as Markov modelling, and they have usually found that newer therapies have favourable cost effectiveness. However, new …, known as exacerbations, and approaches to modelling the cost benefit of exacerbation reduction; (iii) quality …; (v) the limitations of Markov modelling; and (vi) the problem of outliers. …

Persistent link: https://www.econbiz.de/10010569819

A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment

Tarride, Jean-Eric; Hopkins, Robert; Blackhouse, Gord; … - In: PharmacoEconomics 28 (2010) 4, pp. 255-277

Diabetes mellitus is a major healthcare concern from both a treatment and a funding perspective. Although decision makers frequently rely on models to evaluate the long-term costs and consequences associated with diabetes interventions, no recent article has reviewed the methods used in...

Persistent link: https://www.econbiz.de/10008602823

An Outline For a Cost-Effectiveness Analysis of a Drug For Patients With Alzheimer's Disease

Busschbach, Jan J.V.; Brouwer, Werner B.F.; van der … - In: PharmacoEconomics 13 (1998) 1 Part 1, pp. 21-34

This article provides an outline for a cost-effectiveness analysis of a drug that slows the consequences of Alzheimer's disease. Such an analysis cannot easily be performed for 2 main reasons. The first is that often relatives and friends, rather than professionals, take care of the patient....

Persistent link: https://www.econbiz.de/10005404920

Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer's Disease and Other Dementias

Hill, Jerrold; Fillit, Howard; Thomas, Simu K.; Chang, Sobin - In: PharmacoEconomics 24 (2006) 3, pp. 265-280

Introduction: The progressive decline in functional status for patients with Alzheimer's disease and other dementias (ADOD) is well documented. However, there is limited information on the economic benefits of interventions improving functional status in an ADOD population. This study estimated...

Persistent link: https://www.econbiz.de/10005404926

Estimating Long Term Cost Savings from Treatment of Alzheimer's Disease: A Modelling Approach

Fenn, Paul; Gray, Alastair - In: PharmacoEconomics 16 (1999) 2, pp. 165-174

Objective: This paper puts forward a proposal for a modelling approach to the estimation of long term cost savings from … the treatment of Alzheimer's disease (AD). Design: In the proposed modelling approach, disease progression is defined in …

Persistent link: https://www.econbiz.de/10005404968

A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects. The Authors Reply

Salek, Sam S.; Walker, Melvyn D.; Bayer, Anthony J. - In: PharmacoEconomics 16 (1999) 4, pp. 417-419

Persistent link: https://www.econbiz.de/10005404999

The General Public's Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer's Disease Medication

Oremus, Mark; Tarride, Jean-Eric; Raina, Parminder; … - In: PharmacoEconomics 30 (2012) 11, pp. 1085-1095

Background:Background: Alzheimer's disease (AD) is a neurodegenerative disorder highlighted by progressive declines in cognitive and functional abilities. Abstract: Objective:Objective: Our objective was to assess the general public's maximum willingness to pay (MWTP) for an increase in annual...

Persistent link: https://www.econbiz.de/10010579444

Dementia Screening and Surveillance: Are There Opportunities for Early Detection?

Mulligan, Reinhild; Juillerat, Anne-Claude; Van del … - In: Disease Management and Health Outcomes 3 (1998) 4, pp. 173-181

The prevalence of dementia, and in particular Alzheimer's disease, is expected to increase dramatically in the elderly population over the next few decades. Because of the possibilities of pharmacological and psychosocial interventions, which aim to slow down or even prevent progress of the...

Persistent link: https://www.econbiz.de/10005590130

Measuring Outcomes in Alzheimer's Disease Research: Assessment of the Effectiveness of Interventions

Wood, Stacey; Cummings, Jeffrey L. - In: Disease Management and Health Outcomes 5 (1999) 1, pp. 1-12

Alzheimer's disease is a common disorder in the elderly, and a cure is not currently available. This article summarises the intervention studies that have been done in Alzheimer's disease research and discusses assessment tools and outcome measures used in these studies. Current approaches are...

Persistent link: https://www.econbiz.de/10005590201